Management of Prostate Cancer in Central China

NCT01614548 | Completed

• 1 other identifier: ZZU2012
• Study Type: observational
• Target: 789
• Locations: 1 country
• Sites: 1

Brief Summary

Some recent reports indicate that incidence of prostate cancer is increasing rapidly in China. However, no large-scale survey of prostate cancer has been done in central China, few data are available regarding its management. The investigators aimed to analyze the management of prostate cancer and compare the outcome of patients with such a survey. The investigators collected data of patients diagnosed with prostate cancer from the 2003 and 2008 in central China. Data were disaggregated by rural and urban hukou. The survival rate of patients was analyzed using Kaplan-Meier method. Prognostic factors were analyzed using the log-rank test and Cox proportional hazards model.

Conditions

Prostate Cancer

Keywords

Prostatic Neoplasms; Prostate Cancer; Disease Management; Rural; Urban

Outcome Measures

Primary Outcomes (1)

• overall survival

  overall survival that was defined as the interval from the date of diagnosis to the Medicare date of death

  3 years

Study Arms (1)

all patients

We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

all inpatients with prostate cancer in 14 hospitals

You may not qualify if:

• Those with a history of prostate cancer who were treated for another disease were excluded from study.

Sponsors & Collaborators

• Zhengzhou University: lead
• The First Affiliated Hospital of Zhengzhou University: collaborator
• the cancer hospital of Zhengzhou University: collaborator
• Third Affiliated Hospital of Zhengzhou University: collaborator
• People's Hospital of Zhengzhou University: collaborator
• Xinyang Central Hospital: collaborator
• Zhoukou Central Hospital: collaborator
• Center hospital of Nanyang: collaborator
• Center hospital of Shangqiu: collaborator
• Zhumadian Central Hospital: collaborator
• Anyang Regional Hospital: collaborator
• Luoyang Central Hospital: collaborator
• First People's Hospital of Kaifeng: collaborator

Study Sites (1)

the first affiliated hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Liu Bingqian, Ph.D MD

  The First Affiliated Hospital of Zhengzhou University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 2, 2012
• First Posted: June 8, 2012
• Study Start: January 1, 2003
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: June 8, 2012

Record last verified: 2012-06

Locations

CN (1)